drugset / Trial / NCT05154734
Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders
Phase 1/2
Completed
14 enrolled
Tianjin Medical University General Hospital
Tang-Du Hospital · collab
NaSingle-groupOpen-labelBasic science
Summary
Neuromyelitis Optica Spectrum Disorders (NMOSD) is associated with a pathological humoral immune response against the aquaporin-4(AQP-4) water channel. Belimumab (Benlysta ®) is a human immunoglobulin G1λ monoclonal antibody that inhibits B-cell survival and differentiation by neutralizing soluble B lymphocyte stimulator. Belimumab may benefit some patients with NMOSD due to the important role of B cells in the pathogenesis of NMOSD. Clinical trials may be needed to observe its efficacy and safety.
Timeline
- Start
- 2021-12-12
- Primary completion
- 2023-06-30
- Completion
- 2024-04-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belimumab | Monoclonal antibody | 10 mg/kg | Intravenous |